Clinical trials
Locally Advanced Colorectal Cancer clinical trials
Below are recruiting locally advanced colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06487377RecruitingPhase 1
IX001 TCR-T for advanced KRAS-mutated pancreatic and colorectal cancer
This trial tests a new treatment called IX001 TCR-T, which uses your own immune cells to target cancer cells with a specific KRAS mutation. It's for people with advanced pancreatic or colorectal cancer who have run out of standard options.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06500052RecruitingPhase 1
Study of BL-M17D1 for HER2-positive or low-expression digestive tract and other solid tumors
This trial tests a new drug called BL-M17D1 for people with advanced or metastatic HER2-positive or low-expression gastrointestinal cancer and other solid tumors. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06543836RecruitingPhase 2
Targeted therapy plus immunotherapy for advanced colorectal cancer
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Birmingham, AlabamaAges 18 years+ - NCT06603376RecruitingPhase 2
Drug combo for BRAF-mutated advanced colorectal cancer
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
ShanghaiAges 18–80 - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06663839RecruitingPhase 1
Study of NILK-2301 for advanced colorectal cancer
This trial tests a new drug called NILK-2301 for people with colorectal cancer that has spread or cannot be removed. It is for those who have already tried at least one other treatment and have relatively small tumors.
BarcelonaAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06698757RecruitingPhase 2
Testing different cycles of sintilimab before surgery for colorectal cancer
This trial tests how many cycles of the immunotherapy drug sintilimab given before surgery help treat colorectal cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). It is for locally advanced cancer that has not spread to other parts of the body.
Zheng'zhou, HenanAges 18–75 - NCT06342440Recruiting
Early detection of colon cancer and advanced polyps
This study aims to find colorectal cancer and advanced polyps (adenomas) earlier by looking at blood samples. Researchers hope a simple blood test might one day help detect colon cancer before it spreads.
Monrovia, CaliforniaAges 18 years+ - NCT07106034RecruitingPhase 2
Testing a new combo therapy for advanced colorectal cancer
This trial tests a combination of two drugs (ONGERICIMAB and TORIPALIMAB) for people with a specific type of colorectal cancer that did not respond to first treatment. It aims to see if this new approach can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
Miami, FloridaAges 18–90 - NCT06718738RecruitingPhase 1
IM96 CAR-T for advanced colorectal cancer
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06765616RecruitingPhase 2
Immunotherapy with chemo and radiation for rectal cancer before surgery
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Jinan, ShandongAges 18–85 - NCT06776757RecruitingPhase 1/Phase 2
Sintilimab plus cetuximab and chemo for first-line advanced colorectal cancer
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
Shenzhen, GuangdongAges 18–75 - NCT06783491RecruitingPhase 3
Chemotherapy with or without heated chemo for advanced colon cancer
This trial tests if adding heated chemotherapy directly into the abdomen during surgery improves outcomes for people with advanced colon cancer that hasn't spread to other organs. It compares standard chemotherapy before surgery alone versus chemotherapy before surgery plus heated chemo during surgery.
Córdoba, CórdobaAges 18–75 - NCT06791512RecruitingPhase 3
Chemo Plus Targeted Therapy With or Without Immunotherapy for Colorectal Cancer
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
Guangzhou, GuangdongAges 18–80 - NCT06824064RecruitingPhase 2
RBS2418 for advanced metastatic colorectal cancer
This trial tests a new drug called RBS2418 for people with advanced colorectal cancer that has spread and is getting worse, even after other treatments have stopped working. The goal is to see if RBS2418 can help control the cancer.
Newark, DelawareAges 18 years+ - NCT06825624RecruitingPhase 1
Testing HS-20093 combinations for advanced colorectal cancer
This trial tests a new drug combination (HS-20093) for people with advanced colorectal cancer that has spread or cannot be removed by surgery. It aims to see if the combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT06846268RecruitingPhase 2
New drug combo before surgery for colorectal cancer
This trial tests two immunotherapy drugs (ADG126 and pembrolizumab) given before surgery for locally advanced colorectal cancer that hasn't spread. It aims to shrink tumors and improve outcomes.
SingaporeAges 21 years+ - NCT06856187RecruitingPhase 2
Second-line chemo plus TAS-102 combo for advanced colorectal cancer
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Shanghai, Shanghai MunicipalityAges Any age - NCT06867822RecruitingPhase 1
Testing ProAgio for Advanced Colorectal Cancer
This trial tests a new drug called ProAgio for people with advanced or metastatic colorectal cancer. It aims to see if ProAgio can help shrink or slow the cancer when combined with standard treatments.
Birmingham, AlabamaAges 19 years+ - NCT06888843RecruitingPhase 2
Chemotherapy for colorectal cancer in patients 70+
This trial tests two chemotherapy drugs, capecitabine alone or with oxaliplatin, in people aged 70 or older after surgery for stage III colorectal cancer. The goal is to find out which treatment works better to prevent cancer from coming back.
Nizhny NovgorodAges 70–90
Hear when a new Locally Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced colorectal cancer?
- Yes. Clin2 currently lists 283 recruiting locally advanced colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.